Voxelotor (Oxbryta)
Jump to navigation
Jump to search
General information
Class/mechanism: hemoglobin S (HbS) polymerization inhibitor. Voxelotor inhibits hemoglobin S polymerization and red blood cell sickling by increasing the affinity of hemoglobin for oxygen.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 2019-11-25: Granted FDA accelerated approval "for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older." in adults and pediatric patients 12 years of age and older.
- 2021-12-17: Granted FDA accelerated approval "to treat sickle cell disease in pediatric patients aged four up to 11 years" in addition to previous accelerated approval for Oxbryta for patients aged 12 years and older with sickle cell disease.
History of changes in EMA indication
- 2022-02-14: Initial EMA authorization
Also known as
- Code names: GBT-440, GTx-011
- Brand name: Oxbryta